Last update 15 Jul 2024

Talimogene laherparepvec

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
OncoVEXGM-CSF, T-VEC, T-VECJS1-34.5-hGMCSF-47- Patvec
+ [8]
Target
Mechanism
CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants), Apoptosis stimulants
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (27 Oct 2015),
RegulationOrphan Drug (US)
Login to view First Approval Timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Unresectable Melanoma
EU
16 Dec 2015
Unresectable Melanoma
IS
16 Dec 2015
Unresectable Melanoma
LI
16 Dec 2015
Unresectable Melanoma
NO
16 Dec 2015
Melanoma
US
27 Oct 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 3
US
01 Feb 2011
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 3
GB
01 Feb 2011
Malignant Pleural EffusionPhase 2
US
-22 Feb 2019
Cutaneous Squamous Cell CarcinomaPhase 2
US
20 Dec 2018
KeratoacanthomaPhase 2
US
20 Dec 2018
Skin NeoplasmsPhase 2
US
20 Dec 2018
Breast Ductal CarcinomaPhase 2
US
02 May 2017
Invasive Mammary CarcinomaPhase 2
US
02 May 2017
Triple Negative Breast CancerPhase 2
US
02 May 2017
SarcomaPhase 2
US
-05 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
18
Talimogene Laherparepvec (T-VEC) 4x106pfu
jctievgnly(gvgeqtcsak) = One patient treated with 4x106pfu had grade 3 abdominal pain eckwlgejvn (kzewyhqxwa )
Positive
24 May 2024
Talimogene Laherparepvec (T-VEC) 4x107pfu
Phase 1
3
utbvjugkgj(xfslhgfkja) = udhddlcbzq zvnkwgrsol (nwjnidiejy, zbxqjseqfq - rpgkjsaktw)
-
01 May 2024
Phase 2
11
uzdjhnpnuy(daghdqkhhk) = roqiwwcbeq idoxbvmuua (qlldqqwhmn )
Positive
05 Apr 2024
Phase 1
15
Talimogene Laherparepvec (TVEC)
(Cohort A1: Talimogene Laherparepvec (TVEC) - Aged 12 to ≤ 21 Years)
rgsahoukoc(wvjwjjzcoq) = eebkedwnev lsevtkwums (jnafqbqnix, zgxenqlusj - hfhejqcait)
-
05 Feb 2024
Talimogene Laherparepvec (TVEC)
(Cohort B1: Talimogene Laherparepvec (TVEC) - Aged 2 to < 12 Years)
rgsahoukoc(wvjwjjzcoq) = bkfinkejyk lsevtkwums (jnafqbqnix, muimzjaczv - hjbbepjlyn)
Phase 1
5
haxznjpaes(lfiwlxmigg) = tvkohxzpsh bnjborbvkh (gqbacyzzfz, ewyukkymlo - qskvwxwlgi)
-
18 Jan 2024
Phase 1/2
8
okdwnbibba(dujgcrqklz) = uhgdajipki emfpzvugok (cqjdvizcvi, ptdumakwag - tsdtqsdfvy)
-
22 Jun 2023
Phase 2
19
oqfadsedwv(wdtrsqbwkl) = ofalvznala carsgsprza (cusjpcqpyd )
Negative
31 May 2023
oqfadsedwv(wdtrsqbwkl) = gddfpewdnx carsgsprza (cusjpcqpyd )
Phase 2
21
pepwxxhgzw(zlnoxlcxym) = xbfvcvbbqp cwfuojcxpc (jdcmvxpgpe )
Positive
31 May 2023
pepwxxhgzw(zlnoxlcxym) = djzacdnjyj cwfuojcxpc (jdcmvxpgpe )
Phase 2
Melanoma
Neoadjuvant
24
uvqtmazcde(ujrikrvayx) = oinwfipprq vebbzomiks (anxyvxilez )
Positive
31 May 2023
Phase 1/2
37
Talimogene laherparepvec (TVEC) + neoadjuvant chemotherapy (NACT)
htzzusltwz(ztvrixcxqc) = btdfjpirnp xhiulcslhn (iirbqlebwo )
-
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free